In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound. The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
In group A, females will be prescribed oral myoinositol 1g twice daily for 3 months.
In group B, females will be prescribed oral sustained-release metformin 850 mg twice daily for 3 months.
CMH Gujranwala
Guiranwala, Punjab Province, Pakistan
LH/FSH ratio
It will be assessed in terms of ratio between LH and FSH after 3 months of treatment.
Time frame: 3 Months
Regular cycles
It will be labeled if number of days from the start (day 1) of one period until the start (day 1) of the next period are almost equal for at least 3 months
Time frame: 3 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.